
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5311759/publications.pdf Version: 2024-02-01



Μεμμετ ΔηγτΔ1/ ρκ

#	Article	IF	CITATIONS
1	Synthesis and Studies of Anticancer and Antimicrobial Activity of New Phenylurenyl Chalcone Derivatives. Letters in Drug Design and Discovery, 2022, 19, 500-519.	0.7	1
2	TAp73Î <sup>2</sup> Can Promote Hepatocellular Carcinoma Dedifferentiation. Cancers, 2021, 13, 783.	3.7	10
3	Systematic Analysis of Cytostatic TGF-Beta Response in Mesenchymal-Like Hepatocellular Carcinoma Cell Lines. Journal of Gastrointestinal Cancer, 2021, 52, 1320-1335.	1.3	3
4	Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma. , 2021, , 333-364.		0
5	Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer, 2021, 52, 1356-1369.	1.3	2
6	AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization. International Journal of Molecular Sciences, 2021, 22, 13247.	4.1	4
7	Differential expression of full-length and NH <sub>2</sub> terminally truncated FAM134B isoforms in normal physiology and cancer. American Journal of Physiology - Renal Physiology, 2020, 319, C733-G747.	3.4	8
8	Novel Furochromone Derivatives: Synthesis and Anticancer Activity Studies. Journal of Heterocyclic Chemistry, 2019, 56, 1341-1351.	2.6	8
9	Development of a novel zebrafish xenograft model in ache mutants using liver cancer cell lines. Scientific Reports, 2018, 8, 1570.	3.3	29
10	A novel chromonyl thiohydantoin with anti-proliferative action on primary hepatocellular carcinoma cells. Medicinal Chemistry Research, 2018, 27, 153-160.	2.4	1
11	Histone H3.3 regulates mitotic progression in mouse embryonic fibroblasts. Biochemistry and Cell Biology, 2017, 95, 491-499.	2.0	9
12	Phenacyl group containing amide derivative of dehydroabietylamine exhibiting enhanced cytotoxic activity against PLC and MCF7 cancer cell lines. Medicinal Chemistry Research, 2017, 26, 1367-1376.	2.4	9
13	Molecular Pathogenesis of Liver Cancer. Journal of Gastrointestinal Cancer, 2017, 48, 222-224.	1.3	5
14	Thiazolidinedione or Rhodanine: A Study on Synthesis and Anticancer Activity Comparison of Novel Thiazole Derivatives. Journal of Pharmacy and Pharmaceutical Sciences, 2017, 20, 415.	2.1	18
15	Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. OncoTargets and Therapy, 2016, Volume 9, 6843-6855.	2.0	30
16	Role of Fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance. Hepatology Research, 2016, 46, 1264-1274.	3.4	16
17	Synthesis and bio-molecular study of (+)-N-Acetyl-α-amino acid dehydroabietylamine derivative for the selective therapy of hepatocellular carcinoma. BMC Cancer, 2016, 16, 883.	2.6	3
18	Genetics and epigenetics of liver cancer. Toxicology Letters, 2016, 258, S13.	0.8	0

#	Article	IF	CITATIONS
19	Molecular Mechanisms of Hepatocellular Carcinoma. , 2016, , 43-63.		2
20	Liver cancer cells are sensitive to Lanatoside C induced cell death independent of their PTEN status. Phytomedicine, 2016, 23, 42-51.	5.3	33
21	Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World Journal of Gastroenterology, 2015, 21, 311.	3.3	53
22	SAT0583â€The CASE of "Case Reports―in Rheumatology Literature. Annals of the Rheumatic Diseases, 2014, 73, 801.1-801.	0.9	0
23	Synthesis and characterization of amino acid conjugates of oleanolic acid and their in vitro cytotoxic effect on HCC cell lines. Pakistan Journal of Pharmaceutical Sciences, 2014, 27, 1491-6.	0.2	0
24	Comparative evaluation of in vitro cytotoxic effects among parent abietyl alcohol and novel fatty acid ester derivatives against MCF7 and hepatocellular carcinoma cell lines. Pakistan Journal of Pharmaceutical Sciences, 2014, 27, 2013-8.	0.2	0
25	Genetics and epigenetics of liver cancer. New Biotechnology, 2013, 30, 381-384.	4.4	83
26	Genome-Wide Transcriptional Reorganization Associated with Senescence-to-Immortality Switch during Human Hepatocellular Carcinogenesis. PLoS ONE, 2013, 8, e64016.	2.5	61
27	Genetics and epigenetics of liver cancer. New Biotechnology, 2012, 29, S17-S18.	4.4	0
28	Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α. BMC Cancer, 2012, 12, 450.	2.6	24
29	Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Medicine, 2011, 3, 43.	8.2	181
30	Induction of ROS, p53, p21 in DEHP- and MEHP-exposed LNCaP cells-protection by selenium compounds. Food and Chemical Toxicology, 2011, 49, 1565-1571.	3.6	51
31	Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation. Liver International, 2011, 31, 561-571.	3.9	64
32	Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status. Investigational New Drugs, 2011, 29, 1303-1313.	2.6	42
33	Dose- and time-dependent expression patterns of zebrafish orthologs of selected E2F target genes in response to serum starvation/replenishment. Molecular Biology Reports, 2011, 38, 4111-4123.	2.3	1
34	Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010, 684, 106-108.	1.0	10
35	Evaluation of cytotoxicity and oxidative DNA damaging effects of di(2-ethylhexyl)-phthalate (DEHP) and mono(2-ethylhexyl)-phthalate (MEHP) on MA-10 Leydig cells and protection by selenium. Toxicology and Applied Pharmacology, 2010, 248, 52-62.	2.8	171
36	Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets. Cellular Signalling, 2010, 22, 1523-1535.	3.6	17

Mehmet Ķztļrk

#	Article	IF	CITATIONS
37	Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth. Hepatology, 2010, 52, 966-974.	7.3	192
38	The Ability to Generate Senescent Progeny as a Mechanism Underlying Breast Cancer Cell Heterogeneity. PLoS ONE, 2010, 5, e11288.	2.5	17
39	Senescence and immortality in hepatocellular carcinoma. Cancer Letters, 2009, 286, 103-113.	7.2	72
40	Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Molecular Cancer, 2009, 8, 90.	19.2	171
41	Nuclear Exclusion of p33ING1b Tumor Suppressor Protein: Explored in HCC Cells Using a New Highly Specific Antibody. Hybridoma, 2009, 28, 1-6.	0.4	4
42	Homozygosity at variant MLH1 can lead to secondary mutation in NF1, neurofibromatosis type I and early onset leukemia. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 637, 209-214.	1.0	28
43	Immunization with UV-Induced Apoptotic Cells Generates Monoclonal Antibodies Against Proteins Differentially Expressed in Hepatocellular Carcinoma Cell Lines. Hybridoma, 2007, 26, 55-61.	0.4	4
44	The presence of erythropoietin receptor in parathyroid cells. Journal of Endocrinological Investigation, 2007, 30, RC35-RC37.	3.3	5
45	Two novel mutations in the MEN1 gene in subjects with multiple endocrine neoplasia-1. Journal of Endocrinological Investigation, 2006, 29, 523-527.	3.3	7
46	Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncology Reports, 2006, 15, 701.	2.6	65
47	A brother and sister with Werner's syndrome demonstrating extensive tendon calcification and sacroiliitis. Clinical and Experimental Dermatology, 2006, 31, 615-616.	1.3	4
48	Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells. Proceedings of the United States of America, 2006, 103, 2178-2183.	7.1	53
49	Lithium-mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells. International Journal of Cancer, 2005, 115, 903-910.	5.1	63
50	Expression profiling of Wnt pathway genes in breast cancer. Breast Cancer Research, 2005, 7, 1.	5.0	0
51	A New Set of Monoclonal Antibodies Directed to Proline-Rich and Central Regions of p53. Hybridoma, 2004, 23, 287-292.	0.4	2
52	Epidermoid cyst of the testicle: unusual magnetic resonance imaging findings. Acta Radiologica, 2004, 45, 882-884.	1.1	1
53	Acquired tolerance of hepatocellular carcinoma cells to selenium deficiency: a selective survival mechanism?. Cancer Research, 2003, 63, 6707-15.	0.9	45
54	PATIKA: an integrated visual environment for collaborative construction and analysis of cellular pathways. Bioinformatics, 2002, 18, 996-1003.	4.1	135

Менмет öztürk

#	Article	IF	CITATIONS
55	Identification of genes induced by BRCA1 in breast cancer cells. Biochemical and Biophysical Research Communications, 2002, 299, 839-846.	2.1	193
56	p53 mutation as a source of aberrant β-catenin accumulation in cancer cells. Oncogene, 2002, 21, 7971-7980.	5.9	93
57	Molecular characterization of a full genome Turkish hepatitis C virus 1b isolate (HCV-TR1): a predominant viral form in Turkey. Virus Genes, 2002, 25, 169-177.	1.6	14
58	A monoclonal antibody against DNA binding helix of p53 protein. Oncogene, 2001, 20, 1398-1401.	5.9	6
59	Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene, 2001, 20, 5111-5117.	5.9	61
60	NAPO as a novel marker for apoptosis. Journal of Cell Biology, 2001, 155, 719-724.	5.2	14
61	p53 mutations as fingerprints of environmental carcinogens. Pure and Applied Chemistry, 2000, 72, 995-999.	1.9	13
62	The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation Present in Geographically Diverse Populations. American Journal of Human Genetics, 2000, 67, 207-212.	6.2	100
63	Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients. European Journal of Cancer, 2000, 36, 2076-2082.	2.8	22
64	p53 but not p16 INK4a induces growth arrest in retinoblastoma-deficient hepatocellular carcinoma cells. Journal of Hepatology, 2000, 33, 254-265.	3.7	4
65	Genetic Aspects of Hepatocellular Carcinogenesis. Seminars in Liver Disease, 1999, 19, 235-242.	3.6	170
66	Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene, 1999, 18, 4879-4883.	5.9	156
67	Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Research, 1999, 59, 290-3.	0.9	179
68	Thymidine Dinucleotides Induce S Phase Cell Cycle Arrest in Addition to Increased Melanogenesis in Human Melanocytes. Journal of Investigative Dermatology, 1998, 111, 472-477.	0.7	50
69	p21WAF1/CIP1 response to genotoxic agents in wild-type TP53 expressing breast primary tumours. Oncogene, 1997, 14, 45-52.	5.9	31
70	GermlinehMSH2andhMLH1 gene mutations in incomplete HNPCC families. , 1997, 73, 831-836.		18
71	Annexin II up-regulates cellular levels of p11 protein by a post-translational mechanisms. Biochemical Journal, 1996, 313, 51-55.	3.7	78
72	Genomic instability in colorectal cancers in Turkey. , 1996, 68, 291-294.		3

#	Article	IF	CITATIONS
73	Identification of BTG2, an antiproliferative p53–dependent component of the DNA damage cellular response pathway. Nature Genetics, 1996, 14, 482-486.	21.4	384
74	Somatic mutations ofvon Hippel-Lindau (VHL) tumor-suppressor gene in european kidney cancers. International Journal of Cancer, 1995, 63, 660-664.	5.1	38
75	ras, p53 and hpv status in benign and malignant prostate tumors. International Journal of Cancer, 1995, 64, 124-129.	5.1	51
76	p53 Mutations in nonmalignant human liver: Fingerprints of aflatoxins?. Hepatology, 1995, 21, 600-601.	7.3	9
77	p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 1342-1346.	7.1	51
78	Geographic variation of p53 mutational profile in nonmalignant human liver Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Science 1994;264;1317?1319. Hepatology, 1995, 21, 600-601.	7.3	2
79	Genomic stability and wild-type p53 function of lymphoblastoid cells with germ-line p53 mutation. Oncogene, 1995, 10, 2447-54.	5.9	19
80	Genetic heterogeneity of hepatocellular carcinoma Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 822-826.	7.1	156
81	La p53 dans tous ses états : compte-rendu du 8e symposium p53. Medecine/Sciences, 1994, 10, 1021.	0.2	0
82	Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Research, 1994, 54, 2064-8.	0.9	78
83	The effects of cytokines on human chorionic gonadotropin (hCG) production by a trophoblast cell line. Journal of Reproductive Immunology, 1993, 25, 235-247.	1.9	38
84	Retinoblastoma and p <i>53</i> tumor suppressor genes in human hepatoma cell lines. FASEB Journal, 1993, 7, 1407-1413.	0.5	123
85	p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene, 1993, 8, 487-90.	5.9	19
86	The major histocompatibility complex class I antigen-binding protein p88 is the product of the calnexin gene Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 8452-8456.	7.1	80
87	p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet, The, 1991, 338, 1356-1359.	13.7	436
88	Stability of monoclonal antibody-defined epitopes. Journal of Immunological Methods, 1991, 139, 55-64.	1.4	11
89	Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 1991, 350, 429-431.	27.8	1,356
90	Human chorionic gonadotropin, its free subunits and gestational trophoblastic disease. Journal of reproductive medicine, The, 1991, 36, 21-6.	0.2	4

#	Article	IF	CITATIONS
91	Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Research, 1991, 51, 6185-9.	0.9	194
92	Abnormal structure and expression of p53 gene in human hepatocellular carcinoma Proceedings of the United States of America, 1990, 87, 1973-1977.	7.1	386
93	Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma Molecular and Cellular Biology, 1990, 10, 3216-3223.	2.3	71
94	First-trimester maternal serum alpha-fetoprotein and human chorionic gonadotropin screening for chromosome defects. Prenatal Diagnosis, 1990, 10, 575-581.	2.3	26
95	Abnormal maternal serum levels of human chorionic gonadotropin free subunits in trisomy 18. American Journal of Medical Genetics Part A, 1990, 36, 480-483.	2.4	43
96	p53 functions as a cell cycle control protein in osteosarcomas Molecular and Cellular Biology, 1990, 10, 5772-5781.	2.3	779
97	p53 Functions as a Cell Cycle Control Protein in Osteosarcomas. Molecular and Cellular Biology, 1990, 10, 5772-5781.	2.3	324
98	Enhanced expression of an exocrine pancreatic protein in Alzheimer's disease and the developing human brain Journal of Clinical Investigation, 1990, 86, 1004-1013.	8.2	76
99	Enhanced Expression of the Protein Kinase Substrate p36 in Human Hepatocellular Carcinoma. Molecular and Cellular Biology, 1990, 10, 3216-3223.	2.3	21
100	In Vivo expression of two novel tumor-associated antigens and their use in immunolocalization of human hepatocellular carcinoma. Hepatology, 1989, 9, 625-634.	7.3	31
101	Elevated levels of an exocrine pancreatic secretory protein in Alzheimer disease brain Proceedings of the United States of America, 1989, 86, 419-423.	7.1	63
102	Radioimmunolocation of Hepatic and Pulmonary Metastasis of Human Colon Adenocarcinoma. Gastroenterology, 1989, 96, 1317-1329.	1.3	17
103	Identification and characterization of a Mr 50,000 adrenal protein in human hepatocellular carcinoma. Cancer Research, 1989, 49, 6764-73.	0.9	6
104	Characterization of a malignant phenotype-associated cell surface glycoprotein common to various human tumor cells and preferentially expressed on adenocarcinoma of the lung. Cancer Research, 1989, 49, 1349-56.	0.9	7
105	Differential production of human chorionic gonadotropin and free subunits in gestational trophoblastic disease. American Journal of Obstetrics and Gynecology, 1988, 158, 193-198.	1.3	66
106	Physiological Studies of Human Chorionic Gonadotropin and Free Subunits in the Amniotic Fluid Compartment Compared to Those in Maternal Serum*. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 1117-1121.	3.6	27
107	Cell-surface changes associated with transformation of human hepatocytes to the malignant phenotype Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 3140-3144.	7.1	38
108	Physiological Studies of Human Chorionic Gonadotropin (hCG), αhCG, and βhCG as Measured by Specific Monoclonal Immunoradiometric Assays*. Endocrinology, 1987, 120, 549-558.	2.8	155

#	Article	IF	CITATIONS
109	Ectopic β-Human Chorionic Gonadotropin Production by a Human Hepatoma Cell Line (FOCUS): Isolation and Immunochemical Characterization*. Endocrinology, 1987, 120, 559-566.	2.8	17
110	Synthetic peptides and monoclonal antibodies of predetermined specificity in the study of human chorionic gonadotropin. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1987, 14, 295-304.	0.3	0
111	Changes in methionine metabolism induced by d-galactosamine in isolated rat hepatocytes. Biochemical Pharmacology, 1986, 35, 4223-4228.	4.4	7
112	Sensitive and Specific Assay for Human Chorionic Gonadotropin (hCG) Based on Anti-Peptide and AntihCG Monoclonal Antibodies: Construction and Clinical Implications*. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 1319-1327.	3.6	41
113	Identification of epitopes associated with hCG and the beta hCG carboxyl terminus by monoclonal antibodies produced against a synthetic peptide. Journal of Immunology, 1985, 134, 457-64.	0.8	50
114	A Monoclonal Antibody against a Synthetic Peptide Is Specific for the Free Native Human Chorionic Gonadotropin <i>β</i> -Subunit*. Endocrinology, 1984, 115, 330-336.	2.8	24
115	Methionine metabolism and ultrastructural changes with D-galactosamine in isolated rat hepatocytes. Chemico-Biological Interactions, 1984, 51, 63-76.	4.0	11
116	A simple radioactivity assay for measurement of methionine adenosyltransferase activity by aqueous chromatography. Clinica Chimica Acta, 1983, 127, 295-300.	1.1	2
117	3D Organoid modelling of hepatoblast-like and mesenchymal-like hepatocellular carcinoma cell lines. , 0, , .		1
118	TAp73Î $\pm$ is Upregulated in the Most Common Human Cancers. Molecular Biology, 0, , 1.	1.3	0